Protecting Brain Function From Acute and Chronic Insults
Pipeline
Praetego is developing Amadorin candidate PTG-630 to limit neurodegeneration. The mechanism of action is valuable against acute and chronic neuro-insults.
Lead Candidate
PTG-630
From our non-clinical work, PTG-630 demonstrates a wide therapeutic window and minimal risk of drug-drug interactions. With good bioavailability, PTG-630 is well distributed in tissue. It easily crosses the Blood Brain Barrier (BBB). In animal efficacy studies, PTG-630 has consistently demonstrated protection of both the Central Nervous System (CNS) and the Peripheral Nervous System (PNS) in multiple rodent models of neurodegeneration, Alzheimer’s disease, and Diabetic Peripheral Neuropathy. The data demonstrates functional benefit in these models confirmed by direct biochemical measures of neurodegeneration [Amyloid, tau (ptau antibodies), and synaptic markers].
Intended as an oral candidate, PTG-630 is highly absorbed, crosses the blood-brain barrier, and permeates brain tissue.
Chemo Brain in Breast Cancer
As a potent neuroprotective agent, PTG-630 is intended to protect brains from the off-target effects of chemo.
Successfully demonstrating benefit against Chemo Brain proves the biological hypothesis of the Amadorin mechanism of action against neurodegeneration. It serves as a scientific bridge to limiting Alzheimer’s disease.
Alzheimer’s Disease (AD)
PTG-630 is intended to limit mild cognitive impairment due to AD and protect against further progression. From our non-clinical efficacy work, PTG-630 shows tremendous potential to protect a large segment of the AD patient population; and those unlikely to benefit from current options.